Items tagged with Drug-resistant TB
MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for MDR-TB (post)
Abstract
The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains (post)
Summary
National Action Plan for Combating MDR-TB continues to be a work in progress (post)
In December 2015, tuberculosis response advocates welcomed the release of a White House National Action Plan for Combating Multidrug-Resistant Tuberculosis with wary optimism. Promised months earlier as part of a broader administration initiative to tackle antimicrobial resistance, a set of specific goals to counter the growing threat of tuberculosis that does not respond to available medicines would, advocates hoped, inspire funding to support improved treatment and diagnoses of the disease. At the same time, advocates noted, without that funding, the plan would remain nothing more than a plan. They pointed to an earlier initiative with the same name, released by the U.S. Centers for Disease Control and Prevention in 1992 that, unsupported by federal dollars, had never materialized into action or results. And they pointed out that, released in the final week of 2015, the plan had arrived too late to achieve goals that it had set, and aimed to meet “by 2016.”
Mitigating a drug-resistant TB epidemic in Papua New Guinea (post)
A support team for drug-resistant tuberculosis (DR-TB) patients on Daru Island in Papua New Guinea (PNG) aims to provide psycho-emotional support, facilitate adherence and improve the wellbeing of people undergoing treatment. This innovative model engages and empowers the affected community in Daru by training a team of five peer counsellors, called “TB-PALS” (People Affected by, Living with, or having Survived TB) who support patients through 20 months of treatment to cure.
India: Drug to treat MDR-TB to be made available across the country (post)
New Delhi, Apr 11 (PTI) The Centre has decided to expand the availability of Bedaquiline, a drug used for treatment of drug-resistant tuberculosis, across the country, the Rajya Sabha was informed today.
Multidrug-resistant TB in prisons located in former Soviet countries: a systematic review (post)
Abstract
India to expand access to bedaquiline (post)
The central government has decided to increase access to Johnson & Johnson’s anti-tuberculosis drug as part of its efforts to eradicate the disease by 2025, Reuters reported on Monday. The Health Ministry’s TB division chief Sunil Kharpade said the firm’s breakthrough medicine, Bedaquiline, will be available at 140 government-run tuberculosis treatment centres.
Otsuka aims to apply for delamanid approval in India in 90 days (post)
Japanese drugmaker Otsuka Pharmaceutical aims to apply for approval of its tuberculosis (TB) drug delamanid in India within three months, a senior company official said, as calls grow for expanded access to the life-saving medicine.
Drug resistance patterns of drug-resistant TB in Korea (post)
Additional drug resistance patterns among multidrug-resistant TB patients in Korea: implications for regimen design
STREAM community engagement workshop held in Tbilisi, Georgia (post)
The STREAM trial, which is evaluating the effectiveness of shorter treatment regimens for multidrug-resistant tuberculosis (MDR-TB), held a community engagement workshop in Tblisi, Georgia, where the Stage 2 trial is planned to initiate shortly. Stage 2 will study a six-month MDR-TB treatment and a nine-month all oral regimen.
Page 41 of 117 · Total posts: 0
←First 40 41 42 Last→